Comparative Pharmacology
Head-to-head clinical analysis: POKONZA versus TOPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POKONZA versus TOPICORT.
POKONZA vs TOPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Renal (metabolites): ~75%; Fecal: ~25%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid